Pharmacy Medical Policy Updates

The following Pharmacy Medical Policy programs have been updated March 1, 2022:

Effective March 1, 2022:

• Topical Doxepin
• Retinoids
• Enspryng
• Antidepressants
• ACA Prevention Copay Waiver
• Denosumab – Oncology
• Denosumab - Osteoporosis
• Emflaza
• Procysbi
• Progesterones
• Urea Cycle Disorders

Effective April 1, 2022:

• Colony Stimulating Factors
• Acute Migraine Agents
• Cholestasis Pruritus
• Amifampridine
• Oxybate
• Wakix
• VMAT2 Inhibitors
• CFTR
• Xhance
• Arikayce
• Corticotropin

If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.

Institutional Providers
Professional Providers